Tradegate
16.12.25 | 15:56
4,788 Euro
-1,56 % -0,076
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,716 | 4,840 | 22:59 | |
| 4,732 | 4,780 | 22:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.12. | OSE Immunotherapeutics - Strategic plan presented for 2026-2028 | 250 | Edison Investment Research | OSE has announced its strategic plan for the next three years, which is designed to create multiple near-term catalysts. Importantly, it aims to extract maximum value from its lead proprietary candidates... ► Artikel lesen | |
| 09.12. | OSE Immunotherapeutics Unveils 2026-2028 Strategic Plan With Four Opportunities for Value Creation | 4 | GlobeNewswire (USA) | ||
| 08.12. | AbbVie-Deal belastet: Aktie von Ose Immunotherapeutics gibt nach | 20 | Investing.com Deutsch | ||
| OSE IMMUNOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.12. | OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development | 85 | GlobeNewswire (Europe) | OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics' Role in ABBV-230 Development While Preserving... ► Artikel lesen | |
| 17.11. | OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi in Non-Small Cell Lung Cancer | 276 | GlobeNewswire (Europe) | OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer... ► Artikel lesen | |
| 07.11. | OSE Immunotherapeutics Presents a Poster on OSE-Cytomask, a Novel "Cis-Demasking" Cytokine Technology to Increase Therapeutic Index of Immunocytokines | 1 | GlobeNewswire (USA) | ||
| 20.10. | OSE Immunotherapeutics - Refocusing for the next phase | 310 | Edison Investment Research | OSE Immunotherapeutics' H125 results, the first since the board restructuring, reflected normalised operations typical of a clinical-stage biotech, following H124's exceptional licensing income. The... ► Artikel lesen | |
| 15.10. | OSE Immunotherapeutics Reports First Half 2025 Financial Results | 402 | GlobeNewswire (Europe) | OSE Immunotherapeutics Reports First Half 2025 Financial Results NANTES, France, October 15, 2025 - 7:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today reported its consolidated... ► Artikel lesen | |
| 03.10. | OSE ImmunoTherapeutics replaces CEO Nicolas Poirier, appoints Marc Le Bozec as interim CEO | 3 | Seeking Alpha | ||
| 03.10. | OSE Immunotherapeutics Names Marc Le Bozec Interim CEO, Effective Immediately | 1 | RTTNews | ||
| 03.10. | OSE Immunotherapeutics appoints Marc Le Bozec as interim CEO | 10 | Investing.com | ||
| 03.10. | OSE Immunotherapeutics beruft Marc Le Bozec zum Interims-CEO | 2 | Investing.com Deutsch | ||
| 03.10. | OSE Immunotherapeutics: Appointment of Marc Le Bozec as Interim CEO | 142 | GlobeNewswire (Europe) | Appointment of Marc Le Bozec as Interim CEO Nantes, October 3, 2025, 8:00 a.m. CET - OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE) announces the termination of the position as chief... ► Artikel lesen | |
| 30.09. | OSE Immunotherapeutics: Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors | 145 | GlobeNewswire (Europe) | Full renewal of the Board of DirectorsElection of Dr. Markus Cappel as Chairman of the Board of Directors Nantes, September 30, 2025, 7:30 p.m. CET - OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic:... ► Artikel lesen | |
| 26.09. | OSE Immunotherapeutics - Updated cash position; new collaboration | 406 | Edison Investment Research | While OSE Immunotherapeutics' H125 results were previously due to be presented in September, they are now scheduled for 15 October 2025 to allow for the AGM (30 September 2025) to take place ahead of... ► Artikel lesen | |
| 26.09. | Verzögerung bei AbbVie-Partnerschaft belastet Aktie von Ose Immunotherapeutics | 16 | Investing.com Deutsch | ||
| 26.09. | Ose Immunotherapeutics shares fall on AbbVie partnership delay | 5 | Investing.com | ||
| 26.09. | OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy | 3 | GlobeNewswire (USA) | ||
| 23.09. | OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court | 188 | GlobeNewswire (Europe) | OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court NANTES, France - September 23, 2025, 10:30 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) acknowledges... ► Artikel lesen | |
| 22.09. | Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting | 4 | GlobeNewswire (USA) |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,60 | -1,50 % | Rheinmetall Aktie: Sehr spannend! - BioNTech, Evotec, Klöckner, PNE und Stabilus im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| EVOTEC | 5,210 | +0,39 % | Eilmeldung am Abend: EVOTEC SE steht im Brennpunkt | ||
| BB BIOTECH | 48,250 | -1,03 % | Jade Biosciences secures $45 million in private placement from BB Biotech | ||
| MEDIGENE | 0,027 | -8,72 % | MEDIGENE AG stürzt ab - ich traue meinen Augen nicht! | ||
| QIAGEN | 37,990 | -0,90 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| CUREVAC | 4,056 | -5,19 % | Morgen-Update: Curevac sorgt für Spannung - kommt bald die Entscheidung? | ||
| MODERNA | 25,415 | -0,24 % | Moderna, Inc.: EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE | mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the... ► Artikel lesen | |
| VALNEVA | 3,588 | -3,39 % | Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ | IXCHIQ- was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after twelve months in both dose groups... ► Artikel lesen | |
| AMGEN | 276,60 | -0,09 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| NOVAVAX | 5,470 | -2,39 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| STRYKER | 299,40 | 0,00 % | Medizintechnik-Anbieter Stryker hebt erneut Dividende an | ||
| BIOGEN | 144,70 | -3,21 % | Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions | ||
| BIOFRONTERA | 2,660 | -0,37 % | BIOFRONTERA AG: Jetzt kippt das Gleichgewicht! | ||
| HEIDELBERG PHARMA | 2,510 | -7,38 % | HEIDELBERG PHARMA AG: Jetzt könnte die Ruhe trügen! | ||
| ILLUMINA | 111,64 | -2,74 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen |
OSE IMMUNOTHERAPEUTICS SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 4,788 Euro und damit -1,56 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSE IMMUNOTHERAPEUTICS SA finden Sie auf Wallstreet Online.